Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
Abstracts are now available online in the NKF SCM21 Abstract and ePoster Gallery: https://casehippo.com/spa/symposium/national-kidney-foundation-2021-spring-clinical-meetings/event/gallery/browser.
A poster, titled "A Drug-Drug Interaction Study of Vadadustat Coadministered With Cyclosporine, a P-gp Inhibitor, and Digoxin, a P-gp Substrate" (Poster #171), will present Phase 1 clinical research evaluating the effect of cyclosporine on vadadustat exposure and the effect of vadadustat on the exposure of digoxin (Dig). Vadadustat is Akebia's investigational oral hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), which recently completed its global Phase 3 clinical development program for the treatment of anemia due to chronic kidney disease (CKD) in adult patients both on dialysis and not on dialysis.
Additional Akebia and Akebia-sponsored posters include:
- Quality of Life (QoL) and Healthcare Utilization (HRU) in a Phase 4 Study of Ferric Citrate (FC) in Patients With Non–Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Iron Deficiency Anemia (IDA) (Poster #166)
- Predictors of ESA Use in the Non-Dialysis Dependent Chronic Kidney Disease Population with Anemia (Poster #170)
Jeffrey Berns, M.D., who will serve as facilitator and present, "Pathophysiology CKD Anemia and Current Management Strategies;" Volker Haase, M.D., who will present, "Emerging Therapies for CKD Anemia;" and, Stephen Fishbane, M.D., who will present, "Clinical Trials Update: HIF-PHI."
NKF SCM21 attendees can visit the Akebia virtual booth at https://www.akebiavirtualexperience.com/.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat recently completed its global Phase 3 development program for the treatment of anemia due to CKD. Vadadustat is not approved by the
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-poster-presentations-and-educational-symposium-at-national-kidney-foundation-2021-virtual-spring-clinical-meetings-301255231.html